Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Acute Effects of Cannabidiol on Hippocampal Blood Flow in People at Clinical High Risk for Psychosis

View ORCID ProfileCathy Davies, Matthijs G Bossong, View ORCID ProfileDaniel Martins, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, View ORCID ProfileFernando Zelaya, View ORCID ProfilePaul Allen, Michael Brammer, Jesus Perez, View ORCID ProfilePhilip McGuire, View ORCID ProfileSagnik Bhattacharyya
doi: https://doi.org/10.1101/2023.02.22.23286306
Cathy Davies
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cathy Davies
Matthijs G Bossong
3Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Martins
2Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
4National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Martins
Robin Wilson
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Appiah-Kusi
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Blest-Hopley
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Zelaya
2Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernando Zelaya
Paul Allen
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
5School of Psychology, University of Roehampton, London, UK
6Combined Universities Brain Imaging Centre, Royal Holloway University of London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Allen
Michael Brammer
2Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesus Perez
7CAMEO Early Intervention Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
8Institute of Biomedical Research (IBSAL), Department of Medicine, Universidad de Salamanca, Salamanca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip McGuire
9Department of Psychiatry, University of Oxford, Oxford, UK
10NIHR Oxford Health Biomedical Research Centre, Oxford, UK
11Oxford Health NHS Foundation Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip McGuire
Sagnik Bhattacharyya
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sagnik Bhattacharyya
  • For correspondence: sagnik.2.bhattacharyya@kcl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Hippocampal hyperperfusion has been observed in people at Clinical High Risk for Psychosis (CHR), is implicated in the pathophysiology driving psychosis onset and represents a potential disease-modifying treatment target. Whether cannabidiol (CBD) has ameliorative effects on hippocampal blood flow (rCBF) in CHR patients remains unknown.

Methods Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral 600mg dose of CBD or placebo. Nineteen healthy controls were studied under identical conditions but did not receive any drug. Hippocampal rCBF was measured using Arterial Spin Labelling. We examined differences relating to CHR status (controls vs placebo), effects of CBD in CHR (placebo vs CBD) and linear between-group relationships, such that placebo>CBD>controls or controls>CBD>placebo, using a combination of hypothesis-driven and exploratory wholebrain analyses.

Results Placebo-treated patients had significantly higher hippocampal rCBF bilaterally (all pFWE<.01) compared to controls. There were no suprathreshold voxels in the CBD vs placebo contrast. However, we found a significant linear relationship in the right hippocampus (pFWE=.035) such that rCBF was highest in the placebo group, lowest in controls and intermediate in the CBD group. Exploratory wholebrain results replicated previous findings of hyperperfusion in the hippocampus, striatum and midbrain in CHR patients, and provided novel evidence of increased rCBF in inferior-temporal and lateral-occipital regions in patients under CBD compared to placebo.

Conclusions Our findings suggest that CBD may partially normalise alterations in hippocampal blood flow associated with the CHR state and therefore merits further investigation as a potential novel treatment for this population.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ISRCTN46322781

Funding Statement

This study was supported by grant MRJ0121491 from the Medical Research Council, National Institute for Health Research Clinician Scientist Award CS11001, and NIHR Mental Health BRC at SLaM NHS Foundation Trust and King's College London.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Camberwell St Giles gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data produced in the present study are not openly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 24, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Acute Effects of Cannabidiol on Hippocampal Blood Flow in People at Clinical High Risk for Psychosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Acute Effects of Cannabidiol on Hippocampal Blood Flow in People at Clinical High Risk for Psychosis
Cathy Davies, Matthijs G Bossong, Daniel Martins, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, Fernando Zelaya, Paul Allen, Michael Brammer, Jesus Perez, Philip McGuire, Sagnik Bhattacharyya
medRxiv 2023.02.22.23286306; doi: https://doi.org/10.1101/2023.02.22.23286306
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Acute Effects of Cannabidiol on Hippocampal Blood Flow in People at Clinical High Risk for Psychosis
Cathy Davies, Matthijs G Bossong, Daniel Martins, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, Fernando Zelaya, Paul Allen, Michael Brammer, Jesus Perez, Philip McGuire, Sagnik Bhattacharyya
medRxiv 2023.02.22.23286306; doi: https://doi.org/10.1101/2023.02.22.23286306

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Psychiatry and Clinical Psychology
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (520)
  • Anesthesia (124)
  • Cardiovascular Medicine (1417)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10280)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2622)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1728)
  • Health Policy (788)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12080)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2453)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (489)
  • Occupational and Environmental Health (566)
  • Oncology (1318)
  • Ophthalmology (400)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2393)
  • Public and Global Health (4996)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (523)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (255)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)